Compare CLW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | CCCC |
|---|---|---|
| Founded | 1926 | 2015 |
| Country | United States | United States |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.3M | 185.1M |
| IPO Year | 2008 | 2020 |
| Metric | CLW | CCCC |
|---|---|---|
| Price | $14.79 | $2.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $23.00 | $12.20 |
| AVG Volume (30 Days) | 188.6K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,555,400,000.00 | $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | 1.02 |
| 52 Week Low | $12.46 | $1.09 |
| 52 Week High | $30.96 | $3.82 |
| Indicator | CLW | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 55.61 |
| Support Level | $12.46 | $2.26 |
| Resistance Level | $18.85 | $2.85 |
| Average True Range (ATR) | 0.67 | 0.20 |
| MACD | 0.28 | -0.02 |
| Stochastic Oscillator | 91.95 | 90.43 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.